GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Ion Exchange India Ltd-$

Ion Exchange executes technology transfer agreement with MANN+HUMMEL for membrane systems

JV / MOU ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 29 Apr 2026, 03:25 PM IST  ·  BSE ID: 334fb618-9b2e-43a1-a29a-d9d3074e26f2
View Original BSE Filing (PDF)
💡
In Simple Terms
Ion Exchange signed a deal to manufacture advanced water treatment membranes using MANN+HUMMEL's technology, paying 7.5% of sales as royalty.
🤖 AI Summary
  • Ion Exchange executes Technology Transfer Agreement with MANN+HUMMEL for advanced membrane systems
  • Manufacturing scope: PVDF ultrafiltration membranes with UltraSKID systems and membrane bioreactor solutions
  • Production at Ion Exchange's expanded HYDRAMEM® facility in Goa; serves domestic and international markets
  • Technology transfer fee: 7.5% royalty on revenue from manufactured products; includes know-how and best practices
  • Not a related party transaction; agreement entered in ordinary course of business
🔢 Key Numbers — exact figures from BSE filing, not rounded
Technology transfer fee
7.5% on revenue from manufactured products
Manufacturing location
HYDRAMEM® facility, Goa (expanded, state-of-the-art)
Market scope
Domestic and International
🏢 How This Affects the Company
📈
Business Impact
Expands Ion Exchange's addressable market by enabling manufacture and sale of advanced PVDF ultrafiltration and membrane bioreactor systems domestically and internationally. Leverages existing HYDRAMEM® manufacturing facility in Goa to commercialize MANN+HUMMEL's proprietary technology.
💰
Financial Impact
Company incurs 7.5% royalty expense on revenue from manufactured products under the agreement. No upfront lump-sum payment disclosed; cost structure tied to product revenue.
⚙️
Operational Impact
Ion Exchange will undertake system integration, manufacturing, and commercialization of PVDF hollow fiber ultrafiltration membranes using MANN+HUMMEL's advanced technology and best practices at its Goa facility.
⚠️
Risk Impact
Technology transfer agreement creates operational dependency on MANN+HUMMEL's technical support and know-how. Royalty structure (7.5% on revenue) affects product margin competitiveness and pricing flexibility.
👥 What This Means For Shareholders
✅
Action Required
No immediate shareholder action required. Monitor upcoming quarterly results for initial revenue contribution from membrane product lines.
👤
Who Is Affected
All shareholders benefit from expanded revenue streams via new membrane product commercialization. Earnings per share impact depends on royalty economics and production ramp-up timing at Goa facility.
🔍
Management Signal
Management is executing strategic diversification into advanced water treatment membranes by partnering with established global technology leader rather than internal R&D development.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q1 FY27 results — check for initial PVDF membrane revenue contribution from Goa facility
Annual Report FY26 — review detailed terms, royalty payment schedule, and technology transfer timeline
Next update from company — track production ramp-up progress and membrane system commercialization milestones
MEDIUM RISK Margin pressure from 7.5% royalty on all product revenue. Operational dependency on MANN+HUMMEL's technical support and know-how transfer execution.
💡 Investor Takeaway
Ion Exchange has secured technology transfer rights to manufacture advanced PVDF ultrafiltration and membrane bioreactor systems from global partner MANN+HUMMEL. Production at Goa facility serves India and international markets. Cost structure: 7.5% royalty on product revenue. Non-related party transaction executed in ordinary course of business.
⚖️ Strengths & Concerns

✅ Positives

  • Access to MANN+HUMMEL's established PVDF membrane technology reduces development risk and accelerates market entry
  • Both domestic and international commercialization scope provides revenue diversification and growth avenues beyond India

⚠️ Concerns

  • 7.5% royalty on all manufactured product revenue reduces operating margins and competitive pricing flexibility
  • Operational reliance on technology transfer and continuous technical know-how from international partner creates execution dependency
⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.